[In vivo cytogenetic studies of 10-chloro-11b-(2-fluorophenyl)-7-(2-hydroxyethyl)-2, 3, 5, 11b-tetrahydrooxazolo-(3, 2-d) (1, 4) benzodiazepine-6(7H)-one (MS-4101) on rat bone marrow cells (author's transl)].
Chromosome aberrations induced by MS-4101, diazepam, and nitrazepam were studied in Sprague-Dawley rats. Female rats were administered orally via stomach tube daily doses of 200, 500 and 2000 mg/kg of MS-4101, 200 and 500mg/kg of diazepam, 40 and 200mg/kg of nitrazepam and 20 and 50 mg/kg of cylcophosphamide as the positive control for one, 5 and 10 days. In this study, we used bone marrow cells derived from rat femur at 6 or 24 hours after the last drug administration. No significant chromosome aberrations were seen in the treated groups with MS-4101, diazepam, and nitrazepam when compared with the nontreated control. The increase of structural aberration on gap and break was observed in the group of cyclophosphamide as the positive control. These findings indicate that MS-4101, and diazepam and nitrazepam as similar comparative drugs, do not have the potential of induction of chromosome aberrations in rat bone marrow cells.
D000818:Animals; D001570:Benzodiazepinones / Q000008:administration & dosage / Q000633:toxicity*; D001854:Bone Marrow Cells; D002869:Chromosome Aberrations; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000633:toxicity; D003975:Diazepam / Q000008:administration & dosage / Q000633:toxicity; D005260:Female; D009567:Nitrazepam / Q000008:administration & dosage / Q000633:toxicity; D051381:Rats
D001570:Benzodiazepinones; D003520:Cyclophosphamide; D009567:Nitrazepam; D003975:Diazepam